title: Doxycycline does not influence established abdominal aortic aneurysms in angiotensin II-infused mice.
abstract: BACKGROUND
  There is no proven medical approach to attenuating expansion and rupture of abdominal aortic aneurysms (AAAs). One approach that is currently being investigated is the use of doxycycline. Despite being primarily used as an antimicrobial drug, doxycycline has been proposed to function in reducing AAA expansion. Doxycycline is effective in reducing the formation in the most commonly used mouse models of AAAs when administered prior to the initiation of the disease. The purpose of the current study was to determine the effects of doxycycline on established AAAs when it was administered at a dose that produces therapeutic serum concentrations.
  
  
  RESULTS
  LDL receptor -/- male mice fed a saturated-fat supplemented diet were infused with AngII (1,000 ng/kg/min) via mini-osmotic pumps for 28 days. Upon verification of AAA formation by noninvasive high frequency ultrasonography, mice were stratified based on aortic lumen diameters, and continuously infused with AngII while also administered either vehicle or doxycycline (100 mg/kg/day) in drinking water for 56 days. Administration of doxycycline led to serum drug concentrations of 2.3 ± 0.6 µg/ml. Doxycycline administration had no effect on serum cholesterol concentrations and systolic blood pressures. Doxycycline administration did not prevent progressive aortic dilation as determined by temporal measurements of lumen dimensions using high frequency ultrasound. This lack of effect on AAA regression and progression was confirmed at the termination of the study by ex vivo measurements of maximal width of suprarenal aortas and AAA volumes. Also, doxycycline did not reduce AAA rupture. Medial and adventitial remodeling was not overtly changed by doxycycline as determined by immunostaining and histological staining.
  
  
  CONCLUSIONS
  Doxycycline administration did not influence AngII-induced AAA progression and aortic rupture when administered to mice with established AAAs.
authors.affiliation: Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, United States of America.
authors.forename: Xiaojie
authors.initials: X
authors.lastname: Xie
authors.forename: Hong
authors.initials: H
authors.lastname: Lu
authors.forename: Jessica J
authors.initials: JJ
authors.lastname: Moorleghen
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Howatt
authors.forename: Debra L
authors.initials: DL
authors.lastname: Rateri
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Cassis
authors.forename: Alan
authors.initials: A
authors.lastname: Daugherty
mesh_terms: D000284:Administration, Oral; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001012:Aorta, Abdominal / Q000187:drug effects* / Q000473:pathology; D017544:Aortic Aneurysm, Abdominal / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D001019:Aortic Rupture / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D001794:Blood Pressure; D002784:Cholesterol / Q000097:blood; D059305:Diet, High-Fat; D004195:Disease Models, Animal; D004318:Doxycycline / Q000494:pharmacology*; D015918:Infusion Pumps, Implantable; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D011973:Receptors, LDL / Q000172:deficiency / Q000235:genetics; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D011973:Receptors, LDL; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D002784:Cholesterol; D004318:Doxycycline